<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650143</url>
  </required_header>
  <id_info>
    <org_study_id>22021980</org_study_id>
    <nct_id>NCT00650143</nct_id>
  </id_info>
  <brief_title>Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction</brief_title>
  <acronym>SITAGRAMI</acronym>
  <official_title>Safety and Efficacy of Sitagliptin Plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HEINZ NIXDORF-FOUNDATION</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial design:&#xD;
&#xD;
      This Phase III, investigator-driven, randomised, placebo-controlled efficacy and safety study&#xD;
      will compare the effects of Sitagliptin in combination with granulocyte-colony stimulating&#xD;
      factor (Lenograstim, G-CSF) on the improvement of myocardial function in patients undergoing&#xD;
      routine percutaneous coronary revascularisation for acute myocardial infarction (time from&#xD;
      onset of infarction to intervention 2 to 24 hours). The primary objective of this study is to&#xD;
      compare between a treatment of G-CSF plus Sitagliptin, (G-CSF/Sitagliptin treatment group,&#xD;
      n=87) versus Placebo (control treatment group, n=87) in change of global myocardial function&#xD;
      from baseline to 6 months of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted as a multi-centre trial. Secondary objectives of this study are&#xD;
      to monitor changes of regional myocardial function, myocardial perfusion and extent of&#xD;
      non-viable myocardium from baseline to 6 months after revascularisation between the treatment&#xD;
      groups. Furthermore the following parameters over up to 12 months of follow-up are analysed:&#xD;
      occurrence of major adverse cardiac events (death, myocardial infarction, coronary bypass&#xD;
      grafting, or re-intervention), spontaneously reported adverse events. Analyses of cardiac&#xD;
      function consists of evaluation of segmental systolic wall thickening, end-diastolic volume,&#xD;
      end-systolic volume, stroke volume, ejection fraction and cardiac output by means of magnetic&#xD;
      resonance imaging (MRI). The extent of non-viable myocardium and myocardial perfusion will be&#xD;
      assessed using contrast enhanced MRI.&#xD;
&#xD;
      This study consists of a revascularisation period (angioplasty of the infarcted vessel), a&#xD;
      treatment period (up to 28 days), and a follow-up period (up to 12 months). The&#xD;
      Revascularisation Period starts with the treatment of the patient in the emergency room. As&#xD;
      soon as possible the patient will be transferred to the catheterisation laboratory where&#xD;
      acute percutaneous coronary intervention (PCI) of the infarct-related artery will be&#xD;
      performed. The first phase of the Treatment Period consists of a screening period during&#xD;
      which a patient's eligibility is preliminarily evaluated. The second phase of the Treatment&#xD;
      Period is the randomisation for patients in the control or G-CSF/Sitagliptin treatment group.&#xD;
      After baseline MRI, patients are randomised. Patients will be treated either with G-CSF&#xD;
      (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100&#xD;
      mg each day for 28 days or with placebo. Patients will be randomised in 1:1 ratio to the&#xD;
      control and verum therapy treatment groups. Follow-up Period assessments will be performed in&#xD;
      all patients at 6 months including clinical status, occurrence of adverse events, laboratory&#xD;
      investigations, and MRI. To assess occurrence of in-stent restenosis, routine control&#xD;
      angiography will be performed in all patients 6 months after initial PCI. Safety will be&#xD;
      evaluated by monitoring treatment-emergent signs and symptoms, 12-lead ECGs, vital signs,&#xD;
      physical examination, and clinical laboratory assessments after 1 month and 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of global myocardial function from baseline to 6 months of follow-up.</measure>
    <time_frame>Recruitment period: 4,5 years. Follow-up assessment: 1 year. Analyses and reporting: 6 months. Overall duration: 6 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Segmental end-diastolic myocardial thickness, segmental systolic wall thickening, regional contractile reserve, end-diastolic and end-systolic volumes, stroke volume, and cardiac output in MRI</measure>
    <time_frame>6 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of non-viable myocardium will be monitored from baseline up to 6 months measured by MRI delayed enhancement.</measure>
    <time_frame>6 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of myocardial perfusion at rest up to 6 months as measured by signal-time curve parameters using first-pass perfusion MRI</measure>
    <time_frame>6 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major adverse cardiac events (death, myocardial infarction, CABG, or re-intervention) up to 12 months.</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of a treatment of Sitagliptin in combination with G-CSF in CAD patients suffering from MI (spontaneously reported adverse events (AEs) up to 12 months).</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of peripheral blood stem cell populations: CD34, CD34/KDR and CD34/CD26 positive cells prior to and 5 days after therapy initiation.</measure>
    <time_frame>1 week follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma levels of NT-pro-BNP, glucose, complete blood count, CRP, platelets, CK, cTnI prior to and 5 and 28 days, and 6 months after therapy initiation</measure>
    <time_frame>12 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of in stent restenosis using angiography 6 months after facultative PCI</measure>
    <time_frame>6 month follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.&#xD;
n=74</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.&#xD;
n=74</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenograstim (GRANOCYTE)=GCSF</intervention_name>
    <description>10 µg/kg/d s.c. for 5 days divided in two dosages per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin (Januvia)</intervention_name>
    <description>100 mg p.o. per day for 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride (NaCl) 0.9 %</intervention_name>
    <description>applied s.c. twice a day for 5 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelatin</intervention_name>
    <description>One capsule p.o. per day for 28 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Be at least 18 years old, male or female&#xD;
&#xD;
          2. Have acute ST segment elevation myocardial infarction (typical chest pain of more than&#xD;
             30 minutes duration, presence of ST-segment elevation in at least two contiguous leads&#xD;
             or left bundle-branch block) and/or occluded coronary artery&#xD;
&#xD;
          3. Intervention of infarct related artery by PCI/Stenting within 2-24 hours after onset&#xD;
             of acute myocardial infarction.&#xD;
&#xD;
          4. have creatinin kinase elevation of more than three times of upper normal level (i.e.&#xD;
             540 U/l) accompanied by a significant elevation of CK-MB isoenzyme and/or Troponin I/T&#xD;
&#xD;
          5. Have regional wall motion abnormality (comprising hypo-, a- or dyskinesia) of at least&#xD;
             one myocardial segment demonstrated with MRI.&#xD;
&#xD;
          6. Patients who are further suitable for coronary angiography and angioplasty with&#xD;
             stenting of the infarct related artery.&#xD;
&#xD;
          7. Have the ability to understand the requirements of the study, and agree and be able to&#xD;
             return for the required assessments.&#xD;
&#xD;
          8. Give a written informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        General:&#xD;
&#xD;
          1. Women of childbearing potential, pregnancy or being lactating.&#xD;
&#xD;
          2. Be unable to undergo percutaneous cardiac catheterisation&#xD;
&#xD;
          3. Have contraindications against magnetic resonance imaging (e.g. non-MR compatible&#xD;
             implants or medical devices)&#xD;
&#xD;
          4. Have conditions that may severely degrade image quality (e.g. severe arrhythmia) or&#xD;
             prevents from MR scanning (e.g. claustrophobia)&#xD;
&#xD;
          5. Previous enrolment in the present trial or administration of any study medication&#xD;
             within the previous 30 days. Study drug is defined as any material (placebo or drug)&#xD;
             dispensed under the provisions of a protocol.&#xD;
&#xD;
          6. Have other severe concurrent illness (e.g., active infection, malignancy).&#xD;
&#xD;
          7. Life expectancy of less than one year.&#xD;
&#xD;
          8. Have a history of alcohol or drug abuse within 3 months prior to admission or factors&#xD;
             jeopardising follow-up.&#xD;
&#xD;
        Renal, hepatic, metabolic:&#xD;
&#xD;
          1. Moderate to severe renal impairment (Crea level &gt;1.7 mg/dL or glomerular filtration&#xD;
             rate &lt;35 ml/min).&#xD;
&#xD;
          2. Diabetes type 1 patients.&#xD;
&#xD;
          3. Diabetic ketoacidosis.&#xD;
&#xD;
          4. Concomitant medications known to cause hypoglycemia, such as sulfonylureas.&#xD;
&#xD;
          5. Severe liver dysfunction.&#xD;
&#xD;
        Haematologic:&#xD;
&#xD;
          1. Malignant haematological diseases, i.e. chronic myeloic leukemia (CML) or&#xD;
             myelodysplastic syndromes (MDS)&#xD;
&#xD;
          2. Severe congenital neutropenia with cytogenetic abnormalities&#xD;
&#xD;
          3. Known allergic reaction vs. Lenograstim&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          1. Acute cardiogenic shock&#xD;
&#xD;
          2. Cardiomyopathy with an ejection fraction below 0.25 (i.e. ischemic or dilated&#xD;
             cardiomyopathy resulting in congestive heart failure)&#xD;
&#xD;
          3. Infective endocarditis&#xD;
&#xD;
          4. Factors contraindicating cardiac catheterisation (e.g. severe allergy against iodine,&#xD;
             severe thyroid disease)&#xD;
&#xD;
          5. Planned operative revascularisation&#xD;
&#xD;
          6. Left ventricular thrombus&#xD;
&#xD;
          7. Severe cardiac arrhythmias (i.e. malignant sustained or non-sustained ventricular&#xD;
             tachycardia or ventricular fibrillation) within 24 hours after admission.&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          1. Acute massive pulmonary infiltrations&#xD;
&#xD;
          2. History of pneumonia in the last 4 weeks&#xD;
&#xD;
        Other:&#xD;
&#xD;
        1. Therapy with immunosuppressants, cytostatics, corticoids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang M Franz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of the University of Munich-Grosshadern, Department of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang M Franz, Prof. Dr.</last_name>
    <phone>++49-89-7095-6095</phone>
    <email>wolfgang.franz@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans D Theiss, Dr.</last_name>
    <phone>++49-89-7095-3074</phone>
    <email>hans.theiss@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic of the University of Munich-Grosshadern, Department of Cardiology</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans D Theiss, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, Schoenberg SO, Steinbeck G, Franz WM. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol. 2006 Oct 17;48(8):1712-21. Epub 2006 Sep 11.</citation>
    <PMID>17045910</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Principal Investigator: Prof. Dr. Wolfgang-Michael Franz</name_title>
    <organization>Clinic of the University of Munich - Grosshadern, Department of Cardiology</organization>
  </responsible_party>
  <keyword>Stem cell</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>G-CSF</keyword>
  <keyword>CD26-inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

